Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
|
|
- Frederick McDowell
- 6 years ago
- Views:
Transcription
1 Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia Molecolare e Clinica Università Federico II --- Napoli, Italia
2 La terapia anti HER2 nel carcinoma mammario Come ha cambiato la storia naturale?
3 Overall Survival Probability Overall Survival by Trastuzumab Treatment Groups HER2+ / Herceptin Negative No Trastuzumab Trastuzumab HER2-0.2 HER2+ / No Herceptin Months from Diagnosi
4 Trials of 1st-Line HER2+ MBC with Anti-HER2 Based Rx Author Trial Name Agent(s) No. of Pts RR (%) Median TTP (months) Median OS (months) Slamon et al H0684g Paclitaxel Paclitaxel + trastuzumab Slamon et al H0648g Chemotherapy* Chemotherapy* + trastuzumab Marty et al Docetaxel Docetaxel + trastuzumab Perez et al N Paclitaxel (q3w) + carboplatin + trastuzumab Paclitaxel (qw) + carboplatin + trastuzumab Robert et al Paclitaxel + trastuzumab Paclitaxel + trastuzumab + carboplatin Valero et al BCIRG 007 Docetaxel + trastuzumab Docetaxel + carboplatin + trastuzumab Wardley et al CHAT Docetaxel. trastuzumab Docetaxel + capecitabine + trastuzumab (2-yr: 66% 2 yr: 75%) Andersson et al HERNATA Docetaxel + trastuzumab Vinorelbine + trastuzumab Guan Z et al EGF Paclitaxel Paclitaxel + lapatinib
5 Trials of 1st-Line HER2+ MBC with Anti-HER2 Based Rx Author Trial Name Agent(s) No. of Pts RR (%) Median TTP (months) Median OS (months) Slamon et al H0684g Paclitaxel Paclitaxel + trastuzumab Slamon et al H0648g Chemotherapy* Chemotherapy* + trastuzumab Marty et al Docetaxel Docetaxel + trastuzumab Perez et al N Paclitaxel (q3w) + carboplatin + trastuzumab Paclitaxel (qw) + carboplatin + trastuzumab Robert et al Paclitaxel + trastuzumab Paclitaxel + trastuzumab + carboplatin Valero et al BCIRG 007 Docetaxel + trastuzumab Docetaxel + carboplatin + trastuzumab Wardley et al CHAT Docetaxel. trastuzumab Docetaxel + capecitabine + trastuzumab (2-yr: 66% 2 yr: 75%) Andersson et al HERNATA Docetaxel + trastuzumab Vinorelbine + trastuzumab Guan Z et al EGF Paclitaxel Paclitaxel + lapatinib
6 Trials of 1st-Line HER2+ MBC with Anti-HER2 Based Rx Author Trial Name Agent(s) No. of Pts RR (%) Median TTP (months) Median OS (months) Slamon et al H0684g Paclitaxel Paclitaxel + trastuzumab Slamon et al H0648g Chemotherapy* Chemotherapy* + trastuzumab Marty et al Docetaxel Docetaxel + trastuzumab Perez et al N Paclitaxel (q3w) + carboplatin + trastuzumab Paclitaxel (qw) + carboplatin + trastuzumab Robert et al Paclitaxel + trastuzumab Paclitaxel + trastuzumab + carboplatin Valero et al BCIRG 007 Docetaxel + trastuzumab Docetaxel + carboplatin + trastuzumab Wardley et al CHAT Docetaxel. trastuzumab Docetaxel + capecitabine + trastuzumab (2-yr: 66% 2 yr: 75%) Andersson et al HERNATA Docetaxel + trastuzumab Vinorelbine + trastuzumab Guan Z et al EGF Paclitaxel Paclitaxel + lapatinib
7 Probabilità di sopravvivenza Probabilità di sopravvivenza Efficacia di Herceptin con Chemioterapia In pazienti HER2 positiva 3+ ad immunoistochimica Herceptin + chemioterapia Chemioterapia Herceptin + Paclitaxel Paclitaxel Tempo (mesi) Tempo (mesi)
8 Estimated probability M77001: estimated survival 1.0 Herceptin + docetaxel Docetaxel alone p= Months Documented crossover = 44% 9.4 months
9 HERNATA Study
10 HERNATA study : results Time to Progression Overall Survival Andersson JCO 2010
11 HERNATA study: results Time to Treatment Failure Andersson JCO 2010
12 HERNATA study : safety profile Andersson JCO 2010
13 Probability First Line Single Agent Herceptin Time To Progression 1 Responders 0,8 0,6 Non Responders 0,4 0, months
14 Mechanisms of resistance to HER2 directed therapy Loss of trastuzumab binding -(e.g. downregulation of HER expression) Activation of alternative growth factor - (e.g. IGF-1R) Activation of downstream signaling pathways -(e.g. PI3-Kinase)
15 HER2:HER3 dimers have the strongest mitogenic signalling Homodimers Heterodimers HER2:HER2 HER1:HER1 HER3:HER3 HER4:HER4 HER1:HER2 HER1:HER3 HER1:HER4 HER2:HER3 HER2:HER4 HER3:HER Signalling activity Tzahar, et al. Mol Cell Biol 1996
16 Potential new approaches to target HER2-positive breast cancer
17 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Pertuzumab and trastuzumab have complementary mechanisms of action HER2 Pertuzumab Trastuzumab HER1/3/4 Subdomain IV Dimerization domain Trastuzumab: Inhibits ligand-independent HER2 signaling Activates ADCC Prevents HER2 ECD shedding ADCC, antibody-dependent cell-mediated cytotoxicity; ECD, extracellular domain Pertuzumab: Inhibits ligand-dependent HER2 dimerization and signaling Activates ADCC Copyrights for this presentation are held by the author/presenter. Contact them at for permission to reprint and/or distribute. 17
18 Pertuzumab binds to the dimerisation domain of HER2, prevents HER2 forming dimer pairs and may flag cells for destruction by the immune system HER2 HER3 RAS Raf GSK3 MEK mtor Cyclin D1 BAD NF B MAPK p27 apoptosis cell cycle control survival angiogenesis proliferation
19 Study design San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 n=406 Placebo + trastuzumab PD Patients with HER2-positive MBC centrally confirmed (N = 808) 1:1 Docetaxel* 6 cycles recommended Pertuzumab + trastuzumab PD n=402 Docetaxel* 6 cycles recommended Randomization was stratified by geographic region and prior treatment status (neo/adjuvant chemotherapy received or not) Study dosing q3w: Pertuzumab/Placebo: Trastuzumab: Docetaxel: 840 mg loading dose, 420 mg maintenance 8 mg/kg loading dose, 6 mg/kg maintenance 75 mg/m 2, escalating to 100 mg/m 2 if tolerated * <6 cycles allowed for unacceptable toxicity or PD; >6 cycles allowed at investigator discretion MBC, metastatic breast cancer; PD, progressive disease Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 19
20 Study endpoints San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Primary endpoint Independently assessed progression-free survival (PFS) Secondary endpoints PFS by investigator assessment Objective response rate Overall survival Safety Duration of response Evaluation of biomarkers and correlation with clinical outcomes Time to symptom progression Copyrights for this presentation are held by the author/presenter. Contact them at for permission to reprint and/or distribute. 20
21 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Prior therapy for breast cancer Prior (neo)adjuvant chemotherapy, n (%) Yes No Placebo + trastuzumab + docetaxel (n = 406) 192 (47.3) 214 (52.7) Pertuzumab + trastuzumab + docetaxel (n = 402) 184 (45.8) 218 (54.2) Components of (neo)adjuvant therapy*, n (%) Anthracycline Hormones Taxane Trastuzumab 164 (40.4) 97 (23.9) 94 (23.2) 41 (10.1) 150 (37.3) 106 (26.4) 91 (22.6) 47 (11.7) * Numbers add up to more than 100% because patients could have received more than one therapy Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 21
22 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Efficacy results Copyrights for this presentation are held by the author/presenter. Contact them at for permission to reprint and/or distribute.
23 Progression-free survival (%) San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Primary endpoint: Independently assessed PFS n = 433 PFS events n at risk Ptz + T + D Pla + T + D D, docetaxel; PFS, progression-free survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab Ptz + T + D: median 18.5 months Pla + T + D: median 12.4 months Time (months) = 6.1 months HR = % CI p< Stratified by prior treatment status and region Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 23
24 Progression-free survival (%) San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Independently and investigator-assessed PFS Pertuzumab + T + D Placebo + T + D Pertuzumab + T + D Placebo + T + D D, docetaxel; PFS, progression-free survival; T, trastuzumab Independently assessed Investigator-assessed Independent assessment Investigator assessment HR = % CI, ; p< HR = % CI, ; p< Time (months) Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 24
25 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Independently assessed PFS in predefined subgroups Favors pertuzumab Favors placebo n HR 95% CI Prior (neo)adjuvant chemotherapy Region Age group Race All No Yes Europe North America South America Asia <65 years 65 years <75 years 75 years White Black Asian Other Disease type ER/PgR status HER2 status Visceral disease Non-visceral disease Positive Negative Unknown IHC 3+ FISH-positive Unstratified analyses ER, estrogen receptor; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; PgR, progesterone receptor; PFS, progression-free survival Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 25
26 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Independently assessed PFS by prior trastuzumab therapy in patients with (neo)adjuvant therapy Prior (neo)adjuvant trastuzumab treatment (n = 88) No prior (neo)adjuvant trastuzumab treatment (n = 288) Placebo + trastuzumab + docetaxel Median PFS, months Pertuzumab + trastuzumab + docetaxel Median PFS, months Hazard ratio (CI) 0.62 ( ) 0.60 ( ) PFS, progression-free survival Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 26
27 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Independently reviewed objective response In patients with measurable disease at baseline Objective response rate, n (%) Complete response rate, n (%) Partial response rate, n (%) Placebo + trastuzumab + docetaxel (n = 336) 233 (69.3) 14 (4.2) 219 (65.2) Pertuzumab + trastuzumab + docetaxel (n = 343) 275 (80.2) 19 (5.5) 256 (74.6) p = * Stable disease, n (%) 70 (20.8) 50 (14.6) Progressive disease, n (%) 28 (8.3) 13 (3.8) Unable to assess or no assessment, n (%) * The statistical test result is deemed exploratory 5 (1.5) 5 (1.5) Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 27
28 Overall survival (%) San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Overall survival: Predefined interim analysis Median follow-up: 19.3 months, n = 165 OS events HR = 0.64* 95% CI p = * Ptz + T + D: 69 events Pla + T + D: 96 events n at risk Time (months) Pertuzumab + T + D Placebo + T + D * The interim OS analysis did not cross the pre-specified O Brien-Fleming stopping boundary (HR 0.603; p ) D, docetaxel; OS, overall survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 28
29 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Safety results Copyrights for this presentation are held by the author/presenter. Contact them at for permission to reprint and/or distribute.
30 Cardiac tolerability San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Placebo + trastuzumab + docetaxel (n = 397) Pertuzumab + trastuzumab + docetaxel (n = 407) Investigator-assessed symptomatic LVSD* Independently adjudicated symptomatic LVSD* Fall in LVEF to <50% and by 10 percentage points from baseline 1.8% 1.0% 1.0% 1.0% 6.6% 3.8% * LVSD was defined as NYHA class III/IV LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 30
31 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6-10, 2011 Summary and conclusions CLEOPATRA met its primary endpoint and demonstrated a statistically significant and clinically meaningful improvement in PFS (HR = 0.62) in patients with HER2-positive MBC Median PFS increased by 6.1 months from 12.4 to 18.5 months The PFS improvement was consistent across subgroups and supported by the secondary endpoints of ORR and OS (immature) The combination of pertuzumab and trastuzumab plus docetaxel increased rates of diarrhea, rash, mucosal inflammation, febrile neutropenia, and dry skin These adverse events were primarily grades 1 2, manageable, and occurred during docetaxel therapy There was no increase in cardiac adverse events or LVSD This new regimen may be practice-changing in HER2-positive first-line MBC Copyrights for this presentation are held by the author/presenter. Contact them at JBASELGA@PARTNERS.ORG for permission to reprint and/or distribute. 31
32 M77001 & Cleopatra Docetaxel Docetaxel + Tras Docetaxel + Tras Docetaxel + Tras + Pert CR 2% 7% 4% 5.5% PR 32% 54% 65% 75% PD 15% 12% 8% 4% Median TTP (mos) Median OS (mos) >40
33 This new regimen may be practicechanging in HER2-positive first-line MBC Docetaxel + Trastuzumab or Paclitaxel + Trastuzumab Old Standard of Care Docetaxel + Trastuzumab + Pertuzumab New Standard of Care
34 Optimal Therapy in Metastatic Breast- Cancer Do all patients need chemotherapy?
35 TANDEM : Anastrazole +/- Trastuzumab in HER2+/ER+ MBC
36 EGF30008: Lapatinib plus Letrozole in first line HER2/HR+ MBC Johnston S. et al, JCO
37 Tumor Volumes (mm3) Effect of HER Family Inhibitors on Tam-Stimulated Growth E2 Tam Tam+P Complete Responses Tam+P 5/18 Tam+P+T 12/18 Tam+P+T+G 18/ Tam+P+T Tam+P+T+G Days Arpino, JNCI 2007
38 PERTAIN: Phase II trial of pertuzumab in combination with trastuzumab plus an aromatase inhibitor in first line HER2+/HR+MBC
39 PERTAIN: recruitment status
40 Data Driven Practice 1. Most active therapy appears to be a combination of chemothrapy + anti-her2 therapy 2. Most active anti-her2 therapy appears to be a combination of a combination of agents (Trastuzumab + Pertuzumab) 3. Sensitivity to anti-her2 therapies remains despite progression after an anti-her2 agent Similarities to endocrine agents
41 The Future.
42 Trastuzumab emtansine (T-DM1): the first-inclass HER2-targeted antibody-drug conjugate Target expression: HER2 Monoclonal antibody: trastuzumab Cytotoxic agent: DM1 Highly potent chemotherapy (maytansine derivative) Linker Systemically stable Breaks down in target cancer cell T-DM1 42
43 Study Design TDM4450g: ongoing Phase II study of T-DM1 vs trastuzumab + docetaxel in first-line HER2-positive MBC HER2-positive, recurrent locally advanced breast cancer or MBC (N=137) 1:1 Trastuzumab 8 mg/kg loading dose; 6 mg/kg q3w IV + Docetaxel 75 or 100 mg/m 2 q3w (n=70) T-DM1 3.6 mg/kg q3w IV (n=67) PD a PD a Crossover to T-DM1 (optional) Randomized, phase II, international, open-label study b Stratification factors: World region, prior adjuvant trastuzumab therapy, disease-free interval Primary end points: PFS by investigator assessment, and safety Data analyses were based on clinical data cut of Nov 15, 2010 prior to T-DM1 crossover Key secondary end points: OS, ORR, DOR, CBR, and QOL a Patients were treated until PD or unacceptable toxicity. b This was a hypothesis generating study; the final PFS analysis was to take place after 72 events had occurred. 43
44 Proportion progression-free Progression-Free Survival by Investigator Randomized Patients Trastuzumab + docetaxel (n=70) T-DM1 (n=67) Median PFS, mos Hazard ratio % CI Log-rank P value Time (months) Number of patients at risk T+D T-DM Hazard ratio and log-rank P value were from stratified analysis. 44
45 Proportion progression-free Duration of Response by Investigator Patients with Measurable Disease at Baseline with an Objective Response Trastuzumab + docetaxel (n=40) T-DM1 (n=43) Median DOR, mos 95% CI NR a Duration of objective response (months) Number of patients at risk T+D T-DM Kaplan-Meier estimates are shown. a NR, not reached; longer follow-up is needed to estimate the duration of response in the T-DM1 arm. 45
46 Incidence of Hematologic Adverse Events: 30% (All Grade) and/or 5% (Grade 3) of Patients a AE Trastuzumab + docetaxel (n=66) c All grade, n (%) Grade 3 b, n (%) T-DM1 (n=69) c,d Trastuzumab + docetaxel (n=66) c T-DM1 (n=69) c,d Neutropenia e 42 (63.6) 12 (17.4) 40 (60.6) 4 (5.8) Febrile neutropenia 9 (13.6) 0 9 (13.6) 0 Thrombocytopenia e 4 (6.1) 21 (30.4) 2 (3.0) f 6 (8.7) f Leukopenia e 18 (27.3) 6 (8.7) 17 (25.8) 0 Green represents those AEs with 20% difference between treatment arms. a In either treatment arm. b No adverse events listed were grade 5. c Two patients mistakenly received a dose of T-DM1 and were thus included in the T-DM1 arm for safety analyses. d Includes 3 patients who received at least 1 dose of trastuzumab alone or trastuzumab plus docetaxel. e Neutropenia includes events classified as MedDRA preferred terms neutropenia or neutrophil count decreased; thrombocytopenia includes events classified as MedDRA preferred terms thrombocytopenia, platelet count decreased or heparin-induced thrombocytopenia; leukopenia includes events classified as MedDRA preferred terms leukopenia or white blood cell count decreased. f All of these events were grade 3. 46
47 Incidence of Nonhematologic Adverse Events: 30% (All Grade) and/or 5% (Grade 3) of Patients a AE Trastuzumab + docetaxel (n=66) c Green represents those AEs with 20% difference between treatment arms. All grade, n (%) Grade 3 b, n (%) T-DM1 (n=69) c,d Trastuzumab + docetaxel (n=66) c T-DM1 (n=69) c,d Alopecia 44 (66.7) 3 (4.3) e e Fatigue 30 (45.5) 34 (49.3) 3 (4.5) 3 (4.3) Nausea 29 (43.9) 33 (47.8) 0 2 (2.9) Diarrhea 30 (45.5) 11 (15.9) 2 (3.0) 0 Peripheral edema 29 (43.9) 7 (10.1) 3 (4.5) 0 Increased AST 4 (6.1) 27 (39.1) 0 6 (8.7) Pyrexia 15 (22.7) 27 (39.1) 1 (1.5) 0 Headache 12 (18.2) 25 (36.2) 0 0 Back pain 20 (30.3) 18 (26.1) 3 (4.5) 1 (1.4) Increased ALT 4 (6.1) 16 (23.2) 0 6 (8.7) Pneumonia 1 (1.5) 6 (8.7) 0 4 (5.8) a In either treatment arm. b No adverse events listed were grade 5. c Two patients mistakenly received a dose of T-DM1 and were thus included in the T-DM1 arm for safety analyses. d Includes 3 patients who received at least 1 dose of trastuzumab alone or trastuzumab plus docetaxel. e National Cancer Institute Common Terminology Criteria for Adverse Events v.3 only categorizes alopecia as grade 1 or grade 2; there is no grade 3 for this AE. 47
48 Cardiac Safety Cardiac function was assessed locally and centrally based on cardiac ECHO/MUGA Prior anthracycline in the adjuvant setting was 44.8% and 48.6% in the T-DM1 and trastuzumab + docetaxel arms, respectively Asymptomatic LV dysfunction Local assessment LVEF assessment Trastuzumab + docetaxel T-DM1 Patients assessed Patients with post-baseline LVEF 40% 2 a 0 Central assessment Patients assessed Patients with post-baseline LVEF 40% 1 b 0 There were no clinically significant cardiac events reported a Both patients had prior anthracycline therapy in the adjuvant setting; 1 patient received prior trastuzumab therapy in the adjuvant setting. b This patient did not receive prior treatment with an anthracycline. 48
49 Summary and Conclusions This is the first randomized study to evaluate an antibody-drug conjugate for HER2- positive MBC First-line treatment of HER2-positive MBC with T-DM1, compared with trastuzumab + docetaxel was associated with: A significant improvement in PFS (14.2 vs 9.2 mos; HR=0.594; P value=0.0353) Similar ORR but more durable responses (64.2%, median duration not reached vs. 58.0%, median duration 9.5 months) A lower rate of grade 3 AEs (46.4% vs 89.4%) These results validate the hypothesis that the unique properties of T-DM1 may lead to an improved therapeutic index Improved PFS with T-DM1 may result from improved tolerability/duration of treatment/response and intrinsic potency of HER2-targeted DM1 T-DM1 is being evaluated in phase III randomized clinical trials for HER2-positive MBC 49
50 MARIANNE: HER2-positive progressive or recurrent locally advanced BC or previously untreated MBC (n=1092) Primary efficacy objective: T-DM1 + pertuzumab (n=364) Trastuzumab + taxane (n=364) T-DM1 + placebo (n=364) PFS assessed by an independent review facility Primary safety objective: To compare the safety of T-DM1 + pertuzumab or T-DM1 + placebo vs trastuzumab + taxane BC = br east cancer ; MBC = met ast at i c br east cancer ; PFS = pr ogr essi on- f r ee sur vi val 50
Advanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationEmerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ
Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationThe issues that will be resolved through PMCs include the the requalification of bioburden test.
BLA 125409/0_ Perjeta (pertuzumab) 4 patients with normal renal function. No dose adjustment can be recommended for patients with severe renal impairment because of the limited pharmacokinetic data available.
More informationCorporate Medical Policy
Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationJ Clin Oncol 32: by American Society of Clinical Oncology INTRODUCTION
VOLUME 32 NUMBER 19 JULY 1 2014 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationInnovations In The Management Of
Innovations In The Management Of HER2+ Breast Cancer Dr. Sandeep Goyle Consultant Medical Oncologist Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai, India Introduction - Self
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationTITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
TITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Table of Contents Data Supplement 1: Additional Evidence
More informationHighlights in Metastatic Breast Cancer From the 2011 San Antonio Breast Cancer Symposium (SABCS)
February 2012 A SPECIAL MEETING REVIEW EDITION Volume 10, Issue 2, Supplement 2 Highlights in Metastatic Breast Cancer From the 2011 San Antonio Breast Cancer Symposium (SABCS) December 6 10, 2011 San
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationPertuzumab for the adjuvant treatment of HER2-positive breast cancer
Lead team presentation Pertuzumab for the adjuvant treatment of HER2-positive breast cancer 1 st Appraisal Committee meeting Background and clinical effectiveness Committee A Lead team: John McMurray,
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationHER2 Biology and Treatment in Breast Cancer
HER2 Biology and Treatment in Breast Cancer Sandra M. Swain, MD, FACP Director, Washington Cancer Institute Washington Hospital Center Professor of Medicine Georgetown University Washington DC Off-Label
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationRethinking neoadjuvant therapy: neoadjuvant therapy as a platform for drug development in HER2 positive breast cancer
2016.04.29 GBCC luncheon symposium Rethinking neoadjuvant therapy: neoadjuvant therapy as a platform for drug development in HER2 positive breast cancer Seoul National University Bundang Hospital Seoul
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationBreast Cancer: the interplay of biology, drugs, radiation. Prof. L. Livi Università degli Studi di Firenze. Brescia, October 3rd 4th, 2013
Breast Cancer: the interplay of biology, drugs, radiation Prof. L. Livi Università degli Studi di Firenze Brescia, October 3rd 4th, 2013 BACKGROUND (1) The complex interactions between tumor-specific signaling
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationKevin R. Fox, MD Rena Rowan Breast Center Abramson Cancer Center University of Pennsylvania Perelman School of MedicineR
Kevin R. Fox, MD Rena Rowan Breast Center Abramson Cancer Center University of Pennsylvania Perelman School of MedicineR Treatment of early stage, HER2 positive breast cancer Treatment of early stage,
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Trastuzumab Emtansine (Kadcyla) for Metastatic Breast Cancer January 10, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Trastuzumab Emtansine (Kadcyla) for Metastatic Breast Cancer January 10, 2014 DISCLAIMER Not a Substitute for Professional Advice This report
More information